Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
about
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesParallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesInvestigations into Potential Extrasynaptic Communication between the Dopaminergic and Nitrergic Systems.Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome systemControlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans.Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease.Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseEffect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.Non-dopaminergic treatments for motor control in Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Metabotropic glutamate receptors for Parkinson's disease therapy.The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia.Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.Automated one-step radiosynthesis of the CB1 receptor imaging agent [(18) F]MK-9470.Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
P2860
Q26852311-58E8B934-D067-4DDD-852F-8ADB15A4B06DQ30538394-58B387E3-1EFE-48E6-AB24-4B236030EAE4Q30833645-82372476-954E-4895-95C7-C5A85E81BBD9Q34329204-C49B200D-FE71-4CEE-97A4-0194DFE09358Q34440714-C09AC231-6C49-4C54-BC94-9603FE3CF6C2Q34673205-094F484F-744B-450E-BC12-6510BE45C3E1Q34708186-0BBC2D48-0AE7-4375-B9F2-30E052CF8960Q35627045-DCEA38A2-9692-4D28-AA87-DC17A41713FBQ35972575-C1DAF7AF-20D2-4158-9136-33F46F5E96F7Q36186759-01BEADE2-3507-41CC-B5D8-F8B9C62B8065Q36422521-7319B6AA-A276-4F2C-AC19-F87DFB7F3D16Q36936920-9160BC80-6879-49C1-BA9D-08BD02F7EF21Q36936930-EC88D3DF-1A42-4D9D-BC17-A0B4018F4FC9Q37115808-01F0E282-C168-4337-9199-79C725BCCCAAQ37193201-37C0AE7E-4069-4470-BDBA-0BF9A3BFE476Q37209730-75EB9116-3089-4764-A782-2C8ADED01874Q37344109-A5D27DAE-ABA1-4473-88A5-CD190111679FQ37656643-483C46A8-15AF-4B96-AA71-1B47458CC889Q37708588-FC3E9107-C816-45C1-BAFD-99DA8681C8E2Q37712460-6CEC5C7E-6D30-47B2-B0F6-C8E97EE8663AQ38126817-8C1E988C-2F9A-4716-BE6E-B98A915DA1C4Q38262418-BE4CB3E9-7FD2-49DC-9C85-27928DDF1859Q38522769-10E5D9C1-A040-4600-8EE3-C26312F88F24Q38636630-F92DD791-C4DF-4866-800E-3A8619373173Q38947507-4F8FC245-F509-49B7-969D-8E53BD8065C2Q39981493-0956C648-4064-48F9-B54B-238DA6E5FB5CQ41818450-48FAB1E3-1C19-4895-8A02-E56897A39701Q41895369-0F432FE9-442A-443A-88F3-2F1D4CEC5330Q42177230-9C03A52A-9182-4295-BFFE-AA814C36EAC3Q42676936-A313DD01-81FD-43C8-8233-D86DCCCE5F13Q44738958-3DF00A16-066F-462F-961D-1DFD700ADE6EQ46280394-6E7275B1-2B96-4854-B56D-C6A46FA04B13Q47752902-B0105F05-FCA1-4E1A-A1D7-827739651A06Q48050563-5CD9B04C-313F-45E8-8205-DF65C47D08AEQ48585422-EC03DF9B-71E7-438E-A690-8D592DAD3267Q50863573-29008546-017B-4CB0-B651-D48535FEE86BQ52562719-BB94B7AB-BB72-4BC7-B161-C4B67CD8704CQ53096926-46420602-C4DF-419B-A635-7EC8411C0114
P2860
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mechanisms underlying the onse ...... pharmacological manipulation.
@en
Mechanisms underlying the onse ...... pharmacological manipulation.
@nl
type
label
Mechanisms underlying the onse ...... pharmacological manipulation.
@en
Mechanisms underlying the onse ...... pharmacological manipulation.
@nl
prefLabel
Mechanisms underlying the onse ...... pharmacological manipulation.
@en
Mechanisms underlying the onse ...... pharmacological manipulation.
@nl
P2860
P921
P1476
Mechanisms underlying the onse ...... r pharmacological manipulation
@en
P2093
Peter Jenner
P2860
P2888
P304
P356
10.1007/S00702-011-0698-2
P577
2011-09-01T00:00:00Z